Drug or treatment

Afatinib clinical trials

• 7Clinical trials
• 18Countries

Newest trials

All recruiting trials (7)

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

• Combining afatinib and palbociclib for previously treated advanced esophageal squamous cell carcinoma

  This trial tests whether taking afatinib together with palbociclib helps control tumor growth in people with recurrent or metastatic esophageal squamous cell carcinoma who have already received prior treatments.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT06753747

• Afatinib plus chemotherapy to convert unresectable EGFR‑mutant stage III NSCLC into resectable disease.

  This trial will see if afatinib combined with chemotherapy can shrink unresectable, EGFR‑sensitive mutation positive stage III non‑small cell lung cancer enough to allow surgery.

  Recruiting Phase 2 Shandong Public Health Clinical Center · Jinan, Shangdong · NCT06709859

• Using Afatinib to treat patients with Fanconi Anemia and advanced head and neck cancer

  This study is testing if Afatinib can help people with advanced head and neck cancer who also have Fanconi Anemia feel better and improve their condition.

  Recruiting at 2 sites Phase 1/2 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Hanover and 1 other locations · NCT06648096

• Combining Afatinib and Pemigatinib for Advanced Solid Tumors

  This study is testing a combination of two drugs, Afatinib and Pemigatinib, to see if they can safely help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06302621

• Combination of Trastuzumab Deruxtecan and Afatinib for HER2-low Advanced Gastric Cancer

  This study is testing a new combination of two drugs, Trastuzumab Deruxtecan and Afatinib, to see if it can help people with HER2-low advanced gastric cancer who don’t have many treatment choices.

  Recruiting Phase 1/2 Samsung Medical Center · Seoul · NCT06085755

• Evaluating Afatinib for HER2-positive Uterine Serous Carcinoma

  This study is testing if the drug Afatinib can help people with a specific type of uterine cancer that has high levels of HER2 and see how well it works for them.

  Recruiting Phase 2 Yale University · Tucson, Arizona and 2 other locations · NCT02491099

Quick answers

How many clinical trials of Afatinib are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in China (3 trials), United States (3 trials), South Korea (2 trials), Spain (2 trials), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 3, Phase 2: 2, Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →